RCS - Ondine Biomedical - Ondine to present new AMR research at ICPIC Geneva

Ondine BiomedicalAnnouncement

29/08/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230829:nRSc6534Ka&default-theme=true

RNS Number : 6534K  Ondine Biomedical Inc.  29 August 2023

29 August 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine to present new AMR research at ICPIC, Geneva

Ondine Biomedical to present new research on efficacy of photodisinfection
against key gram-negative bacteria driving antimicrobial resistance threat

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present
new research on the efficacy of antimicrobial photodynamic therapy, known as
photodisinfection, against extensively drug-resistant gram-negative bacteria
at the 7 (https://conference.icpic.com/) (th (https://conference.icpic.com/) )
International Consortium on Prevention & Infection Control (ICPIC)
(https://conference.icpic.com/) taking place in Geneva, from 12-15 September
2023. ICPIC is a leading international conference on the prevention of
healthcare-associated infection and the control of antimicrobial resistance
around the world.

Antimicrobial resistance (AMR) poses an urgent global public health threat.
The US has shown an alarming increase of 35% in AMR Enterobacteriaceae
infections( i  (#_edn1) ) and analysis published in The Lancet found that 1.27
million deaths worldwide in 2019 were the direct result of drug-resistant
bacterial infections.( ii  (#_edn2) ) Extensively drug-resistant (XDR)
bacteria are a particularly concerning category of multidrug-resistant
organisms that are proving resistant to almost all or all approved
antimicrobial agents.( iii  (#_edn3) )

Dr. Nicolas Loebel, Ondine's CTO and President, commented:

"Overuse of antibiotics over decades has caused adaptation in many microbes,
and we now see multidrug resistance (MDR) evolving into extensive drug
resistance (XDR) in bacteria, rendering even the most powerful drugs
ineffective. We believe photodisinfection can play a significant role in cost
effectively combatting these drug-resistant pathogens and reducing global
reliance on antibiotics."

Photodisinfection is an easy-to-use alternative to antibiotics and
antifungals, including MDR  and XDR strains, because it is highly effective
against all types of disease-causing pathogens and, as a non-biological
treatment, does not generate resistance.

Ondine's photodisinfection is a patented technology using a proprietary
photosensitizer that when illuminated with a specific wavelength of
non-thermal red light, causes an oxidative burst that produces reactive oxygen
species that are lethal to bacteria, fungi, algae, protozoa and viruses, by
utilizing multi-target action mechanisms. Ondine is a previous winner of an
ICPIC Innovation Award of Excellence for its clinical and pre-clinical work
demonstrating photodisinfection efficacy against numerous SARS-CoV-2 strains.

The poster presentation, "Antimicrobial Photodynamic Therapy Against
Extensively Drug-Resistant (XDR) Gram-Negative Isolates With Novel Antibiotic
Resistance Factors", will be presented at ICPIC from 1pm CET on 13 September
2023. A further announcement will be released by the Company concurrent with
the start of the presentation at ICPIC.

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

 

 

 i  (#_ednref1) CDC. COVID-19: U.S. Impact on Antimicrobial Resistance,
Special Report 2022. Atlanta, GA: U.S. Department of Health and Human
Services, CDC; 2022. doi:https://dx.doi.org/10.15620/cdc:117915

 ii  (#_ednref2) The Lancet, Volume 399, Issue 10325, P629-655, February 12,
2022 https://doi.org/10.1016/S0140-6736(21)02724-0
(https://doi.org/10.1016/S0140-6736(21)02724-0)

 iii  (#_ednref3)
https://www.news-medical.net/health/What-are-Extensively-Drug-Resistant-(XDR)-Bacteria.aspx
(https://www.news-medical.net/health/What-are-Extensively-Drug-Resistant-(XDR)-Bacteria.aspx)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGZRRLFGFZG